Placebo and Nocebo Responses in Pharmacological Trials of Tic Disorders: A Meta‐Analysis
Movement Disorders · 2024
DOI: 10.1002/mds.29714 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Movement Disorders, 2024. Verfasst von Simeng Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Nocebo Effect, Placebo Effect, Tic Disorders. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Science and Technology Innovation Project of China Academy of Chinese Medical Sciences.
Abstract (Originalsprache)
Background
Clinical trials of new drugs for tic disorders (TD) often fail to yield positive results. Placebo and nocebo responses play a vital role in interpreting the outcomes of randomized controlled trials (RCTs), yet these responses in RCTs of TD remain unexplored.
Objective
The aim was to assess the magnitude of placebo and nocebo responses in RCTs of pharmacological interventions for TD and identify influencing factors.
Methods
A systematic search of the Embase, Medline, Cochrane Central Register of Controlled Trials, and PsycINFO databases was conducted. Eligible studies were RCTs that compared active pharmacological agents with placebos. Placebo response was defined as the change from baseline in TD symptom severity in the placebo group, and nocebo response as the proportion experiencing adverse events (AEs) in this group. Subgroup analysis and meta‐regression were performed to explore modifying factors.
Results
Twenty‐four trials involving 2222 participants were included in this study. A substantial placebo response in TD symptom severity was identified, with a pooled effect size of −0.79 (95% confidence interval [CI] −0.99 to −0.59; I 2 = 67%). Forty‐four percent (95% CI 27% to 63%; I 2 = 92%) of patients experienced AEs while taking inert pills. Sample size, study design, and randomization ratio were correlated with changes in placebo and nocebo responses.
Conclusion
There were considerable placebo and nocebo responses in TD clinical trials. These results are of great relevance for the design of future trials and for clinical practice in TD.
Systematic review registration
PROSPERO registration ID CRD42023388397. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
- School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine, Beijing, China.
- Department of Traditional Chinese Medicine, Children's Hospital of Soochow University, Soochow, China.
- Chinese EQUATOR Center, Hong Kong Chinese Medicine Clinical Study Center, Chinese Clinical Trial Registry (Hong Kong), School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, China.
ORCID-Profile: Fei Han
Förderung
- The Science and Technology Innovation Project of China Academy of Chinese Medical Sciences
Zitieren
APA
Wang, S., Xiong, Z., Cui, Y., Fan, F., Zhang, S., Jia, R., Hu, Y., Li, L., Zhang, X., & Han, F. (2024). Placebo and Nocebo Responses in Pharmacological Trials of Tic Disorders: A Meta‐Analysis. Movement Disorders. https://doi.org/10.1002/mds.29714
Vancouver
Wang S, Xiong Z, Cui Y, Fan F, Zhang S, Jia R, et al. Placebo and Nocebo Responses in Pharmacological Trials of Tic Disorders: A Meta‐Analysis. Movement Disorders. 2024. doi:10.1002/mds.29714
BibTeX
@article{Wang2024,
author = {Wang, Simeng and Xiong, Zhiyi and Cui, Yuehua and Fan, Fei and Zhang, Si and Jia, Ru and Hu, Yuchen and Li, Liang and Zhang, Xuan and Han, Fei},
title = {Placebo and Nocebo Responses in Pharmacological Trials of Tic Disorders: A Meta‐Analysis},
journal = {Movement Disorders},
year = {2024},
doi = {10.1002/mds.29714}
}
EUVIMED